EICHOR
● Not Yet Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
Condition: HNSCC · Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
About this study
This is a multicenter, open-label, Phase II clinical study to assess the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571 in participants with recurrent or metastatic HNSCC.
This description comes directly from the study's public registry record.
Talk to the study team
Xin Li · +86 10 58302512 · lixin@kelun.com
Always discuss trial participation with your own doctor first.
Locations (2)
| West China Hospital, Sichuan University | Chengdu, China | — |
| Shanghai Oriental Hospital | Shanghai, China | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07668154